Spero Therapeutics, Inc. (SPRO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Spero Therapeutics, Inc. (SPRO) closed at USD 1.12 on 2026-10-14, a change of -52.9 % over the past year, with a market capitalization of USD 65.81M.

Spero Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Spero Therapeutics, Inc. key figures

Previous close

USD 1.12 (2026-10-14)

1-year change

-52.9 %

Market cap

USD 65.81M

Enterprise value

USD 17.07M

P/E ratio (trailing)

8.69

P/E ratio (forward)

-1.02

EPS (trailing)

0.13

EPS (forward)

-1.11

PEG ratio

n/a

Price to book

1.49

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.06

Employees

25

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Spero Therapeutics, Inc. and compare it with other stocks.